Lessons from LIBRETTO-431 Trial in RET+ NSCLC
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
Patrick Forde Post Conference Perspectives Non Squamous Disease Ret Targeted Ret Fusion Oncogene Subtypes
Source: ajmc.com